{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-235212","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.524959+00:00","generated_at":"2026-05-17T04:13:37.844107+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains","bullets":["All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.","22 developmental milestones gained across domains of communication, fine motor, gross motor.","Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).","Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.","Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-235212","json":"https://secwatch.observer/filing/0001193125-25-235212.json","markdown":"https://secwatch.observer/filing/0001193125-25-235212.md","text":"https://secwatch.observer/filing/0001193125-25-235212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/0001193125-25-235212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:13:37.844107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}